The biopharmaceutical industry stands at a crossroads with its very future in question. The problem is deep-seated, arising from serious structural flaws in the way the industry has been constructed. Incremental innovations are no longer sufficient. The industry needs a radical transformation, and Asia offers a unique opportunity for remodeling the system. The pre-requisite, however, is that biopharmaceutical companies truly comprehend the emergence—or re-emergence—of Asia, and meet the challenge of understanding local, thinking local and being local. Contract Research Organizations (CROs), with their cross-industry view of the landscape, must understand their pivotal role within the new “wheel-and-spoke” partnership model, and evolve from being pure service providers to becoming key enablers of healthcare transformation in Asia.
About the Author
Dr. Amar Kureishi joined Quintiles in August 2010 to establish the Strategic Drug Development Unit (SDD Asia). With a mission to help biopharmaceutical companies formulate clinical development and regulatory strategies for their products, SDD Asia rapidly gained an international following, helping ten clients devise Asian strategies for 15 different compounds in its start-up year. Prior to joining Quintiles, Dr. Kureishi was Global Head of Medical Affairs for Bayer, responsible for all therapeutic areas within the worldwide Bayer Healthcare organization. During his 11-year career with Bayer, Dr. Kureishi held progressively senior leadership positions across different geographies, including posting in the USA, Germany, China and Singapore. In 2005, he was assigned to China as Vice President and Head of Clinical Development & Medical Affairs for Asia-Pacific with a remit to build Bayer’s clinical development capabilities and infrastructure in China and Asia-Pacific, resulting in the accelerated development of products such as Nexavar and Xaralto.